Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

FIND, a co-op partner of the World Health Organization, has included Selfdiagnostics in their 2017-2020 project pipeline for tuberculosis diagnostics. Selfdiagnostics is one of the TOP 20 projects in the Sputum-based and drug susceptibility testing area that was given this priority status.

FIND has referenced Selfdiagnostics’ technology – a lab level accurate and fully disposable rapid self-test, in its tuberculosis (TB) pipeline. This test would allow end users to detect disease in a non-invasive, fast and convenient way. Tests in TB pipeline have advanced past the feasibility stage and therefore meet FIND’s priority diagnostic needs in order to fight tuberculosis (TB) in the world. Tuberculosis is one of the TOP 10 causes of death worldwide and diagnosing it remains a major challenge. The current “gold standard” test is smear microscopy, which omits too many cases and therefore simpler and more sensitive TB tests are urgently needed.

Currently our product for TB detection is estimated to be released at the beginning of 2019.

FIND is an international non-profit organization that enables the development and delivery of much-needed diagnostic tests for tuberculosis, malaria, HIV/AIDS, hepatitis C and several other infectious diseases. FIND has an active collaboration with the World Health Organization deciding and effectively implementing diagnostic solutions worldwide.